i-SENS has applied for a change in authorization to expand the age range for use of its continuous glucose monitoring (CGM) device CareSens Air to include children and adolescents.


i-SENS Applies for Marketing Authorization Change to Expand CGM Age Range View original image

According to i-SENS on November 23, the application is intended to expand the eligible users of CareSens Air, which is currently approved and sold in South Korea for diabetes patients aged 19 and older, to include children and adolescents aged 2 and older.


Once approval from the Ministry of Food and Drug Safety is complete, CareSens Air will be available to pediatric and adolescent patients, enabling the company to expand prescriptions and distribution channels in pediatric and adolescent care. Because initial experience with a product is likely to lead to long-term use among children and adolescents, the expansion also has significance for growing the customer base over the medium to long term.


Earlier, i-SENS obtained CE change certification to expand the age range for use of CareSens Air to include children and adolescents. Through this domestic application, the company plans to expand its CGM user base to include children and adolescents both in South Korea and abroad.



An i-SENS official said, "This application is intended to make CareSens Air available to diabetes patients across a broader age range. We will respond diligently to the Ministry of Food and Drug Safety's review and continue to expand our CGM user base in South Korea and abroad."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing